Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Asparec; JZP-416; mPEG-R-crisantaspase; PEG-crisantaspase; Pegylated-crisantaspase; PEGylated-Erwinia-chrysanthemi-L-asparaginase; Polyethylene-glycol-Erwinia-chrisanthemi-L-asparaginase

Latest Information Update: 26 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alize Pharma II SAS
  • Developer EUSA Pharma; Jazz Pharmaceuticals Inc
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Amidohydrolase stimulants; Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in France (IV, Infusion)
  • 06 Jan 2016 Jazz Pharmaceuticals terminates phase II trial in Acute Lymphoblastic Leukemia in USA (NCT02257684)
  • 02 Mar 2015 Jazz Pharmaceuticals suspends enrolment in a phase II/III trial for Acute lymphoblastic leukaemia (Second-line therapy or greater, In adolescents, In children, In infants) in USA (NCT02257684)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top